Applied Genetic Technologies (AGTC) Misses Q3 EPS by 4c, Sales Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. CHKP
5. CRWD
6. ON
7. HNGE
8. INSP
9. MRVL
10. MTCH

Go back to Applied Genetic Technologies (AGTC) Misses Q3 EPS by 4c, Sales Miss

AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2017

May 10, 2017 4:08 PM EDT

GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended March 31, 2017.

In the past quarter, we completed enrollment in the dose escalation portion of the Phase 1/2 clinical trial for our XLRS product candidate and are scheduling patients for enrollment in XLRS as well as for ACHMB3 and ACHMA3 Phase 1/2 clinical trials, said Sue... More